Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study

Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study

Abstract Background Immune checkpoint inhibitors (ICI) combined with chemotherapy are efficacious for treating advanced non-small cell lung cancer (NSCLC); however, the effectiveness of this approach in the malignant pleural effusion (MPE) population is unclear. This study evaluated ICI plus chemoth...

Full description

Bibliographic Details
Main Authors: Qi Wei, Taibing Deng, Junhua Wu, Hao Zeng, Chang Qi, Sihan Tan, Yuanyuan Zhang, Qin Huang, Xin Pu, Weiguo Xu, Weimin Li, Panwen Tian, Yalun Li
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Malignant pleural effusion
Immunotherapy
Chemotherapy
Efficacy
Online Access:https://doi.org/10.1186/s12885-024-12173-1

Internet

https://doi.org/10.1186/s12885-024-12173-1

Similar Items